Stockscreener 앱 받기
9.22
3.65%
0.325
시간 외 거래:
9.04
-0.18
-1.95%
전일 마감가:
$8.895
열려 있는:
$8.79
하루 거래량:
220.36K
Relative Volume:
1.26
시가총액:
$121.26M
수익:
$1.93M
순이익/손실:
$-7.96M
주가수익비율:
-0.00261
EPS:
-3530.8178
순현금흐름:
$-36.78M
1주 성능:
+1.60%
1개월 성능:
+47.52%
6개월 성능:
+28.77%
1년 성능:
+3.48%
1일 변동 폭
$8.41
$9.29
1주일 범위
$8.41
$9.80
52주 변동 폭
$3.39
$16.00
아발로 테라퓨틱스 Stock (AVTX) Company Profile
명칭
Avalo Therapeutics Inc
전화
410-522-8707
주소
1500 LIBERTY RIDGE DRIVE, WAYNE
AVTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AVTX
Avalo Therapeutics Inc
|
9.22 | 119.16M | 1.93M | -7.96M | -36.78M | -3,530.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.36 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
591.01 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
458.31 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.97 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
309.33 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
아발로 테라퓨틱스 Stock (AVTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-15 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-06-02 | 재개 | H.C. Wainwright | Buy |
| 2025-03-25 | 개시 | Jefferies | Buy |
| 2025-03-25 | 개시 | Stifel | Buy |
| 2025-02-28 | 개시 | Piper Sandler | Overweight |
| 2025-02-21 | 개시 | Wedbush | Outperform |
| 2024-12-19 | 개시 | BTIG Research | Buy |
| 2024-10-24 | 개시 | H.C. Wainwright | Neutral |
| 2024-04-16 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2021-09-24 | 개시 | RBC Capital Mkts | Outperform |
모두보기
아발로 테라퓨틱스 주식(AVTX)의 최신 뉴스
Is Avalo Therapeutics Inc. Forming a Bottom PatternGap Up & Growth-Oriented Investment Plans - classian.co.kr
Is Avalo Therapeutics Inc. forming a bottoming baseJuly 2025 News Drivers & Safe Entry Trade Signal Reports - Newser
News impact scoring models applied to Avalo Therapeutics Inc.July 2025 Outlook & Growth Focused Entry Reports - Newser
Quantitative breakdown of Avalo Therapeutics Inc. recent movePortfolio Value Summary & Daily Stock Trend Watchlist - Newser
Should you hold or exit Avalo Therapeutics Inc. nowPortfolio Update Summary & Entry Point Strategy Guides - Newser
Will Avalo Therapeutics Inc. benefit from macro trendsTrade Volume Summary & High Accuracy Trade Signal Alerts - Newser
How to track smart money flows in Avalo Therapeutics Inc.Trade Analysis Summary & Real-Time Buy Zone Alerts - Newser
What institutions are buying Avalo Therapeutics Inc. stock nowTrade Risk Summary & Fast Entry Momentum Alerts - beatles.ru
Can swing trading help recover from Avalo Therapeutics Inc. lossesQuarterly Growth Report & Long-Term Capital Growth Ideas - Newser
Avalo Therapeutics: Speculative Buy Ahead of AVTX-009's LOTUS Results - AInvest
Avalo Therapeutics: Speculative Buy Ahead Of AVTX-009’s LOTUS Results (NASDAQ:AVTX) - Seeking Alpha
How to forecast Avalo Therapeutics Inc. trends using time seriesJuly 2025 Trade Ideas & Long-Term Growth Portfolio Plans - Newser
Is Avalo Therapeutics Inc. forming a reversal patternMarket Activity Summary & AI Driven Stock Price Forecasts - Newser
Avalo Therapeutics Inc. stock outlook for YEARShort Setup & Real-Time Volume Triggers - Newser
Avalo Therapeutics Inc. stock momentum explainedCPI Data & Stock Portfolio Risk Management - Newser
Developing predictive dashboards with Avalo Therapeutics Inc. dataJuly 2025 PostEarnings & Weekly Watchlist for Hot Stocks - Newser
Using RSI to spot recovery in Avalo Therapeutics Inc.Weekly Stock Report & Short-Term High Return Ideas - Newser
Buy Signal for Avalo Therapeutics Inc. Stock Key Technical Indicators to WatchJuly 2025 WrapUp & Fast Gain Swing Alerts - Newser
Chart based exit strategy for Avalo Therapeutics Inc.July 2025 Trade Ideas & Smart Money Movement Alerts - Newser
Avalo Therapeutics Initiated with Overweight Rating by Cantor Fitzgerald - AInvest
Can Avalo Therapeutics Inc. recover in the next quarterWeekly Trend Summary & Target Return Focused Picks - Newser
Avalo Therapeutics Gains as Cantor Fitzgerald Initiates Coverage with Bullish View on Lead Asset AVTX-009. - AInvest
Avalo stock gains after Cantor bullish view (AVTX:NASDAQ) - Seeking Alpha
Cantor Fitzgerald initiates Avalo Therapeutics stock with Overweight rating - Investing.com
Cantor Fitzgerald Initiates Avalo Therapeutics at Overweight - MarketScreener
Avalo Therapeutics initiated with an Overweight at Cantor Fitzgerald - TipRanks
Should you wait for a breakout in Avalo Therapeutics Inc.Forecast Cut & Free Technical Pattern Based Buy Signals - Newser
Avalo Therapeutics, Inc. (NASDAQ:AVTX) Short Interest Update - Defense World
Is Avalo Therapeutics Inc. reversing from oversold territoryEarnings Summary Report & Growth Oriented Trade Recommendations - Newser
Avalo Therapeutics Reports Q2 2025 Financial Results - MSN
Avalo Therapeutics Inc.’s Beta Climbs After Market VolatilityEarnings Trend Report & Weekly Market Pulse Updates - sundaytimes.kr
Avalo Therapeutics: Oppenheimer Maintains Buy Rating with $35 Price Target - AInvest
아발로 테라퓨틱스 (AVTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
아발로 테라퓨틱스 주식 (AVTX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Almenoff June Sherie | Director |
Nov 12 '24 |
Buy |
12.50 |
500 |
6,250 |
500 |
2.44%
0.09%
자본화:
|
볼륨(24시간):